The Annual European Society for Medical Oncology (ESMO) 2025 Congress was held in Berlin, Germany October 17 to October 21, 2025. This year’s ESMO was the biggest one yet, with almost 3000 abstracts presented and over 100 late breakers. Once again, the congress showcased multiple practice-changing breakthroughs across a number of different cancers and settings. It was another big year for antibody drug-conjugates, from Enhertu’s success in early-stage HER2+ breast cancer, to Padcev in perioperative MIBC, and sac-TMT in EGFRm NSCLC. Novel approaches challenged conventions, with ctDNA becoming an increasingly useful tool to help to guide treatment strategies. Not all results were positive, Roche, as a matter of transparency and good science, detailed multiple tiragolumab failures across the SKYSCRAPER trials.

This post-meeting report features commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.

A full list of ESMO events is also available for download as an Excel file.